Wednesday Jul 9, 2025
NEWSLETTER
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
Home News

The future is here: Israeli researchers develop nanotechnology to fight cancer

The use of nanoparticles assists the body's immune system to fight cancer as they eliminate obstacles in the malignant tumor's environment that impede the normal activity of natural killer cells.

by  JNS and ILH Staff
Published on  08-11-2022 12:16
Last modified: 08-11-2022 12:51
The future is here: Israeli researchers develop nanotechnology to fight cancerGetty Images/iStockphoto

Barda-Saad has no doubt that this technology is a sign of the future. | File photo: Getty Images/iStockphoto

Share on FacebookShare on Twitter

Bar-Ilan University researchers have developed a new technology that enables the use of nanoparticles to assist the body's immune system to fight cancer.

Follow Israel Hayom on Facebook, Twitter, and Instagram

According to the research, published in the journal EMBO Molecular Medicine, the nanoparticles are used to eliminate obstacles in the malignant tumor's environment that impede the normal activity of natural killer cells (a special sub-type of white blood cells called lymphocytes).

Natural killer cells, or NK cells, are a potent defense weapon of the body that assists the immune system in its fight against viral infections, tumor growth and the spread of cancerous metastases. Cancer researchers have known that natural killer cells have important potential to treat cancer by immunotherapy since they have the ability, under certain circumstances, to readily and efficiently kill cancer cells and attack them directly.

NK cells can produce a potent immune response in the vicinity of the tumor, known as the tumor microenvironment. Still, despite their great promise, several obstacles make it difficult for researchers and physicians to utilize killer cells for immunotherapy, including the need to manipulate them by means of molecular/genetic engineering outside the body in order to enhance their therapeutic efficacy against cancer.

Moreover, no clinical study performed to date has demonstrated the superiority of NK-cell-based treatments in patients with advanced cancer. The reason is due to the fact that the tumor microenvironment usually activates inhibitory mechanisms that suppress the activity of NK cells.

To overcome these obstacles, Professor Mira Barda-Saad and her research associates at Bar-Ilan's Mina and Everard Goodman Faculty of Life Sciences developed a mechanism to incorporate lipid-based nanoparticles into the NK cells. The procedure "packs" RNA molecules in a lipid envelope, and once penetrated, they interfere with the expression of the gene responsible for inactivating the NK cells.

The nanoparticles target the killer cells inside the patient's body, are incorporated into them and by means of a biochemical reaction enable them to fulfill their task – namely, reducing the tumor mass. The significance of this innovation is that this novel nanotechnology mechanism can prove to be very efficient in applying already established medical approaches based on NK cells, as well as other treatments.

Lipid particle nanotechnology used as an RNA vehicle is a field-proven technology, as was demonstrated in the COVID-19 vaccine, but in contrast to the immune system, Barda-Saad uses it in her laboratory to temporarily "silence" gene expression aimed at enhancing the immune response in pathological conditions.

"Our research proved the feasibility of using nanoparticles to enhance immune-system activity, in this case of NK cells, against human hematological malignancies. Going forward, particles will be created that can be administered orally to patients," Barda-Saad said. "This strategy must still be submitted for pre-clinical and clinical safety testing, as is customary for any drug. Its use can be extended beyond cancer only; viral infections and other pathological conditions can also be addressed by NK cells as well as by other cell types in the immune system, such as T or B lymphocytes, and for other pathologies."

Subscribe to Israel Hayom's daily newsletter and never miss our top stories!

The idea to develop nanoparticles is derived from the fact that they eliminate the need to purify and isolate patients' cells outside the body as in the strategies currently used for treating blood cancers, such as chimeric antigen receptor (CAR)-NK or CAR-T. The nanoparticles are administered to the patient, and they can independently identify the specific target cell while in the body, penetrate it and alter its behavior according to their contents.

In this research, the nanoparticles specifically identify the NK cells, thanks to the antibody attached to their surface. The NK cells target the nanoparticles, engulf them and the material enclosed therein is released inside the cell, enabling the natural killer cells to perform their task.

Barda-Saad added that immunotherapy, especially that which is based on NK cells, is gaining increasing importance in medicine.

"At present, the scientific world is focusing on treatment strategies involving NK cells, because it has been proven that in some aspects, they are superior to T cells, another variety of immune system cells," she explained. "Therefore, therapeutic strategies with NKs are evolving. The nanoparticles we developed can further empower these strategies."

Barda-Saad has no doubt that this technology is a sign of the future.

"The use of nanoparticles in this innovative and groundbreaking domain of next-generation immunotherapeutic drugs enhances the immune response against pathogens that cause illness," she said. "We saw that this technology was successful in Pfizer's and Moderna's COVID vaccines, and I firmly believe that by combining it with the right molecules detected in our laboratory we will be able to harness it in the fight against cancer."

Reprinted with permission from JNS.org.

Related Posts

After surviving Gaza captivity: Former hostages get engagedCourtesy

After surviving Gaza captivity: Former hostages get engaged

by Noam Dvir

Former Gaza hostages Sasha Troufanov and Sapir Cohen have announced their engagement in the United States, where they are currently...

Iran War 2.0? Trump, Netanyahu have different ideasEPA/ALEXANDER DRAGO / POOL; Satellite image ©2025 Maxar Technologies / AFP; REUTERS/Evelyn Hockstein;

Iran War 2.0? Trump, Netanyahu have different ideas

by Erez Linn

When they met on Monday and Tuesday Trump and Netanyahu basked in the glow of their triumph over Iran. But...

Leaked recording exposes Trump's threats to Putin, XiKevin Lamarque/Reuters

Leaked recording exposes Trump's threats to Putin, Xi

by Adi Nirman

Newly released recording from 2024 reveals the president told both leaders he would strike their capitals.

Menu

Analysis 

Archaeology

Blogpost

Business & Finance

Culture

Exclusive

Explainer

Environment

 

Features

Health

In Brief

Jewish World

Judea and Samaria

Lifestyle

Cyber & Internet

Sports

 

Diplomacy 

Iran & The Gulf

Gaza Strip

Politics

Shopping

Terms of use

Privacy Policy

Submissions

Contact Us

About Us

The first issue of Israel Hayom appeared on July 30, 2007. Israel Hayom was founded on the belief that the Israeli public deserves better, more balanced and more accurate journalism. Journalism that speaks, not shouts. Journalism of a different kind. And free of charge.

All rights reserved to Israel Hayom

Hosted by sPD.co.il

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il

Newsletter

[contact-form-7 id=”508379″ html_id=”isrh_form_Newsletter_en” title=”newsletter_subscribe”]

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il